Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Friesenbichler, J; Maurer-Ertl, W; Bergovec, M; Holzer, LA; Ogris, K; Leitner, L; Leithner, A.
Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors.
Sci Rep. 2017; 7(1):1736-1736 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Bergovec Marko
Friesenbichler Jörg
Holzer Lukas
Leithner Andreas
Leitner Lukas
Maurer-Ertl Werner
Ogris Kathrin
Gendermonitor:
Altmetrics:

Number of Figures: 2
| |
Abstract:
Artificial bone graft substitutes, such as Calcibon, are becoming increasingly interesting as they do not cause donor site morbidity which is an advantage compared to autologous bone grafts. The aim of this study was to evaluate the efficacy and potential complications associated with the use of Calcibon. Twenty-seven patients with benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity. Based on the radiological classification system of Neer, these lesions only comprised Grade I lesions, describing cysts that only require curettage and filling, but no additional treatment. At a mean follow up of six months we observed radiological consolidation without resorption of the bone graft substitute. These observations were also made at a mean follow-up of 13 and 32 months, respectively. According to the classification system of Goslings and Gouma we observed six surgical complications. Summing up, Calcibon seems to be a reliable bone graft substitute with low complication rates. However, delayed resorption should be expected. Calcibon seems to be an alternative to autologous bone grafts or allografts in adequate indications.

© Meduni Graz Impressum